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Synthesis and properties of a series of carboranyl-BODIPYs
Jaime H. Gibbs, Haijun Wang, N. V. S. Dinesh K. Bhupathiraju, Frank R. Fronczek,
Kevin M. Smith and M. Graça H. Vicente*
Department of Chemistry, Louisiana State University, Baton Rouge, LA 70803, USA

Dedicated to Professor Russell Grimes on the occasion of his 80 th birthday

Abstract: A series of four BODIPYs containing one or two ortho- or para-carborane
clusters were synthesized using palladium(0)-catalyzed Suzuki cross-coupling or
nucleophilic substitution reactions, at the 2,6- or the 8-positions of halogenated boron
dipyrromethenes (BODIPYs). The spectroscopic, structural (including one X-ray) and in
vitro BBB permeability of the BODIPYs using hCMEC/D3 brain endothelial cells were
investigated.
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1. Introduction
BNCT is a binary treatment that operates through the reaction of low energy
thermal or epithermal neutrons with
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B-containing drug molecules localized within

tumor cells. Upon capture of a neutron, the stable isotope of boron-10 is converted into
the highly reactive boron-11 isotope which readily undergoes fission, releasing high
linear energy transfer (high-LET) alpha and lithium-7 particles,  radiation and
approximately 2.4 MeV of kinetic energy [1,2]. The high-LET particles have limited path
lengths in tissue (less than 10 µm), therefore limiting the devastation effects to cells
containing boron-10. As a result, BNCT potentially functions as a very selective and
localized therapy, able to destroy boron-containing tumors without damaging the
remaining healthy tissues. Consequently, research over the last few decades has focused
on the development of tumor-selective boronated molecules capable of delivering the
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necessary therapeutic dose of 15-30 µg boron-10/g tumor to infected cells with minimal
damage to normal tissues [3,4]. Although the natural abundance of boron-10 is 20%, this
isotope can be incorporated into BNCT agents at the 95% level from the corresponding
boron-10 enriched starting material.
BNCT is particularly promising for the treatment of malignant brain tumors due
to the deep penetration of epithermal neutron beams (up to 10 cm). However, treating
diseases of the brain imposes its own challenges, predominantly as a result of the
selective permeability of the blood brain barrier (BBB). The BBB is a highly selective
physical and metabolic protective barrier surrounding the brain, which serves to protect
the homeostatic environment of the brain. Necessary nutrients for proper brain function
bypass the BBB via several transport mechanisms, including paracellular diffusion, ion
symports and antiports, transcellular diffusion, cation channels, active transport, and
receptor-adsorptive mediated endocytosis [5,6]. Tight junctions limit paracellular
diffusion of molecules and fluid into and out of the brain, preventing diseases and viruses
from attacking the sensitive brain tissue. The investigation of several types of molecules,
including peptides, sugars, liposomes and porphyrins, using hCMEC/D3 cell monolayers
as BBB model [7-9], has shown that several structural and physical factors play a role in
their ability to permeate the BBB, including size, conformation, lipophilicity, and
molecular weight [10-12].
Two boronated compounds are approved for clinical use as BNCT agents, the
sodium salt of the sulfhydryl boron hydride Na2B12H11SH known as BSH, and L-4dihydroxy-borylphenylalanine known as BPA [4]. Although BSH and BPA have
demonstrated low toxicity and efficacy in BNCT clinical trials [13,14], improved BNCT
agents with higher tumor selectivity, including boronated amino acids, antibodies,
nucleosides, sugars, lipids, liposomes, and porphyrin derivatives, have been the focus of
research. Herein we report the synthesis, spectroscopic properties, and BBB permeability
of a new type of low molecular weight BNCT agent, known as BODIPY (4,4-difluoro-4bora-3a,4a-diaza-s-indacene) [15,16], containing one or two ortho- or para-carborane
clusters. The neutral isomeric carboranes, ortho-, meta-, and para-C2B10H12, are
generally the clusters of choice for attachment to boron delivery agents, because of their
high boron content, lipophilic properties, and their high kinetic and hydrolytic stabilities
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[17]. Two synthetic routes were explored for the synthesis of carborane-substituted
BODIPYs: a Suzuki cross-coupling reaction between a carborane-containing boronic acid
and a 2,6-diiodo- or a 8-chloro-BODIPY, and a nucleophilic substitution reaction
between a thiol-containing carborane and a 8-chloro-BODIPY.

2. Materials and Methods

2.1 Synthesis and characterization

2.1.1 General. Reagents and solvents were acquired from Sigma-Aldrich, Fisher
Scientific, or TCI and used without further purification. Reactions were monitored by
TLC using 0.2 mm silica plates with UV indicator (UV254). Column chromatography
was performed using Sorbent Technologies 60Ȧ silica gel (230 - 400 mesh). Merck TLC
silica gel 60 glass plates were used for preparative thin layer chromatography. The 1H
NMR and
1
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C NMR spectra were obtained using a Bruker DPX-400 spectrometer (400

MHz for H, 100 MHz for
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C) with samples dissolved in deuterated chloroform using

tetramethylsilane as an internal indicator. Chemical shifts (δ) are given in ppm and
coupling constants (J) in Hertz (Hz). High resolution ESI mass spectra were obtained
using an Agilent Technologies 6210 ESI-TOF mass spectrometer at the Louisiana State
University Mass Spectrometry Facility.
BODIPYs 1 [18], 4 [19], 7 [19] and methyl-o-carborane phenyl boronic acid 2
[20] were prepared as previously reported.

2.1.2. BODIPY 3. BODIPY 1 (0.02 g, 0.03 mmol), methyl-o-carborane phenyl boronic
acid 2 (0.04 g, 0.13 mmol), and Pd(PPh3)4 (0.004 g, 0.003 mmol) were dissolved in dry
toluene (2 mL) over 3Å molecular sieves. A solution of 1M Na2CO3 (0.5 mL) was added
and the mixture was stirred at reflux for 15 hours. The reaction was quenched with water
and extracted with CH2Cl2. The combined organic layers were dried over Na2SO4 and the
solvent was evaporated. The resulting residue was purified by silica gel column
chromatography using a gradient from hexanes to 50:50 hexanes/CH2Cl2 as eluent to
obtain a red crystalline solid (0.025 g) in 89% yield. 1H-NMR (400 MHz, CDCl3) δ 8.21-
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8.20 (d, J = 8, 2H), 7.50-7.48 (d, J = 8, 2H), 7.23-7.21 (d, J = 7.8, 4H), 7.15-7.13 (d, J =
7.8, 4H) 3.96 (s, 3H), 3.48 (s, 4H), 2.8-1.5 (br m, 22H), 2.56 (s, 6H), 2.18 (s, 6H), 1.30 (s,
6H);
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C-NMR (100 MHz, CDCl3) δ 166.40, 157.74, 140.79, 140.09, 139.11, 133.99,

133.35, 133.27, 130.95, 130.89, 130.53, 130.34, 130.31, 128.42, 77.44, 74.86, 52.45,
40.94, 23.73, 13.50, 13.03; MS (ESI-TOF) m/z 874.6523 [M+H]+, calcd for
C41H57B21F2N2O2: 874.6488.
2.1.3. BODIPY 5. BODIPY 4 (0.01 g, 0.035 mmol), methyl-o-carborane phenyl boronic
acid 2 (0.022 g, 0.074 mmol), and Pd(PPh3)4 (0.004 g, 0.0035 mmol) were dissolved in
dry toluene (2 mL) over 3Å molecular sieves. A solution of 1M Na2CO3 (0.5 mL) was
added and the mixture was stirred at reflux for 15 h. The reaction was quenched with
water and extracted with CH2Cl2. The combined organic layers were dried over Na2SO4
and the solvent was evaporated. The resulting residue was purified by preparative thin
layer chromatography using 5:1 hexanes/ethyl acetate as eluent to obtain an orange solid
(0.008 g) in 47% yield. 1H-NMR (400 MHz, CDCl3) δ 7.35-7.33 (d, J = 7.8, 2H), 7.317.30 (d, J = 7.8, 2H) 5.99 (s, 2H), 3.55 (s, 2H), 3.0-1.0 (br m, 10H), 2.56 (s, 6H), 2.20 (s,
3H), 1.40 (s, 6H);
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C-NMR (100 MHz, CDCl3) δ 155.75, 142.98, 140.73, 135.84,

131.27, 128.41, 123.20, 121.38, 95.34, 82.90, 71.40, 41.07, 37.50, 14.57, 13.93; MS
(ESI-TOF) m/z 495.3772 [M+H]+, calcd for C23H34B11F2N2: 495.3786.
2.1.4. BODIPY 6. A solution of BODIPY 4 (56.4 mg, 0.2 mmol), 1-mercapto-1,2carborane (45.6 mg, 0.24 mmol) and K2CO3 (41.5mg, 3.0 mmol) in THF (30 ml) was
stirred at room temperature for 12 h or until the starting material was consumed. The
solvent was removed in vacuo and the residue was taken up in CHCl3 and washed with
water, brine and then dried over anhydrous Na2SO4. The product was purified by silica
gel column chromatography using CH2Cl2/hexane as eluent and was obtained as a red
solid in 94% yield. 1H NMR (400 MHz; CDCl3) δ 6.15 (s, 2H), 2.57 (s, 6H), 2.49 (s, 6H),
2.20-1.70 (m, 11H); 13C NMR (CDCl3) δ 158.91, 143.66, 129.61, 123.83, 135.66, 60.07,
17.15, 15.10; MS (ESI-TOF): m/z 423.2871 [M+H]+, calcd for C15H24B11F2N2S:
423.2882.
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2.1.5. Crystal data. Diffraction data were collected at low temperature on a Bruker Kappa
Apex-II DUO diffractometer with MoK radiation ( = 0.71073 Å). Refinement was by
full-matrix least squares using SHELXL, with H atoms in idealized positions. Crystal
data for BODIPY 6: C15H25B11F2N2S, triclinic P-1, a=10.903(2), b=13.495(3),
c=16.700(3) Å, =113.823(9), =103.287(9), =94.166(10)°, Z=4, T=100K, max=36.7°,
R=0.038 for 17341 data with I>2(I) (of 21133 unique), 567 parameters, two
independent molecules, CCDC 1056580.

2.1.6. Absorption and Fluorescence Spectroscopy. The spectroscopic properties of
BODIPYs 3 and 5-7 were determined on solutions prepared by dissolving crystalline
compound in DMSO. Stock solutions (5 x 10-5 M) were prepared and diluted to
appropriate concentrations for collection of absorbance and emission spectra. Absorption
spectra were obtained on a Varian Cary 50 Bio UV-Vis spectrophotometer.
Measurements obtained for determining optical density were taken from solutions with
concentrations between 1.2 x 10-5 and 5 x 10-5 M so that λmax was between 0.5 and 1.0.
Fluorescence measurements were recorded on solutions with concentrations between 1.2
x 10-6 and 2.5 x 10-5 M to attain an optical density at the excitation wavelength between
0.04 and 0.06. Compounds were excited at 500 nm for 3, 480 nm for 5, 480 nm for 6, and
490 nm for 7. Emission spectra were acquired on a PTI QuantaMaster4/2006SE
spectrofluorimeter with the slit width set at 3 nm. Rhodamine 6G was used as a standard
in calculating the fluorescence quantum yields (Φf = 0.95 in ethanol) [16]. All
measurements, both absorbance and emission, were acquired within 4 h of solution
preparation at room temperature (23 – 25 °C), using a 10 mm path length quartz
spectrophotometric cell.

2.2. BBB Permeability.
The hCMEC/D3 cells were incubated in a 6-well, 0.4 μm porosity PET transwell plate
(Corning) and allowed to grow for 48 h. EBM-2 medium containing 5% FBS (fetal
bovine serum), 1% penicillin-streptomycin, hydrocortisone, ascorbic acid, chemically
defined lipid concentrate (1/100), HEPES, and bFGF was used. Samples of 0.5 mL for
each BODIPY and standard lucifer yellow at a concentration of 1 mg/ml were used. To
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determine the BODIPY and standard concentrations in the lower chamber that mimicks
the cerebral compartment, fluorescence emission was read at 520/590 and 420/540 nm
(excitation/emission), respectively, using a BMG FLUOstar plate reader. The
permeability coefficients (Pe, expressed in cm/s) were determined following the
clearance principle, as previously reported [12,21]. A value of Pe = 25.23 ± 0.88 x 10-6
cm/s was determined under the above conditions for the standard lucifer yellow.

2.3. Octanol-HEPES buffer partition coefficients.
The partition coefficients (log P) were measured at room temperature by adding 0.5 mL
of a BODIPY stock solution in DMSO (50 µM) to a 15 mL volumetric tube containing
4.0 mL of HEPES buffer (1 M, pH 7.4), followed by addition of 4.0 mL of 1-octanol.
After vortexing for 5 min, the phases were allowed to separate completely. An aliquot of
0.5 mL from each layer was diluted with 0.5 mL of methanol and the absorbance was
measured on a Varian Cary 50 Bio UV-Vis spectrophotometer with a 10 mm path length
quartz cuvette.

3. Results and Discussion

3.1. Syntheses and structural characterization
Halogenated BODIPYs are versatile starting materials for functionalization via
palladium(0)-catalyzed cross-coupling reactions, such as Stille, Suzuki and Sonogashira,
at the -(3,5)- or -(2,6)-pyrrolic carbons, and at the meso-8-position [19,22-26]. In
particular, para-carborane clusters have been previously introduced at the 2,6-positions
via Sonogashira cross-coupling of a 2,6-diiodo-BODIPY with 1-ethynyl-p-carborane
[26]. Based on these studies, we decided to explore another palladium(0)-catalyzed crosscoupling, the Sukuki reaction, for the preparation of carborane-containing BODIPYs.
Symmetric 2,6-diiodo-BODIPYs, such as 1, can be easily obtained in four steps
by condensation of 2,4-dimethylpyrrole with the corresponding aryl aldehyde, followed
by oxidation, boron complexation, and iodination reactions [18]. We have previously
reported that BODIPY 1 shows very low cytotoxicity (IC50 > 200 M) in human HEp2
cells [18], an important property of a potential BNCT agent, and its methyl ester group
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allows the introduction of further functionality via hydrolysis and conjugation with
alcohols or amines [27]. The Suzuki coupling reaction of BODIPY 1 with o-carboranecontaing boronic acid 2 [20], under similar conditions to those previously reported for
bromo-BODIPYs [25], produced BODIPY 3 in 89% yield after purification, as shown in
Scheme 1. The ortho-carborane clusters were stable under the basic conditions used in
the reaction, and no deboronated byproducts were observed.
Under similar reaction conditions, chloro-BODIPY 4 [19] reacted with boronic
acid 2 [20] producing BODIPY 5 in 47% yield, as shown in Scheme 2. The lower yield
obtained for the cross-coupling reaction at the 8- versus the 2,6-positions is likely a result
of the lower reactivity of chlorine versus iodine under the cross-coupling conditions. We
have recently reported that in polychlorinated BODIPYs, palladium(0)-catalyzed Stille
cross-coupling reactions occur regioselectively first at the 8-position, followed by the
3,5- and the 2,6-positions [28].

Scheme 1. Synthesis of BODIPY 3 via Suzuki coupling of BODIPY 1 and o-carboranesubstituted boronic acid 2.
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Scheme 2. Synthesis of BODIPYs 5 – 7 from 8-chloro-BODIPY 4 via Suzuki coupling
with 2, or by nucleophilic substitution using 1-mercapto-ortho-carborane or 1mercaptomethyl-para-carborane.

In addition to cross-coupling reactions, 8-halogenated-BODIPYs, such as 4, can
also undergo nucleophilic substitutions in the presence of S-, N- and O-centered
nucleophiles [19,29]. Using this strategy, BODIPY 4 reacted with commercially available
1-mercapto-ortho-carborane in the presence of K2CO3 in THF, to give BODIPY 6 in 94%
yield (Scheme 2). Unlike the Suzuki cross-coupling reaction, the nucleophilic substitution
at the most electrophilic 8-position afforded the target BODIPY in high yield. We have
previously reported the synthesis of BODIPY 7 from reaction of 4 with 1mercaptomethyl-1,12-carborane in high yield [19]. Under these conditions boron
substitution was not observed, however, we have previously substituted the para-fluoro
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phenyl groups of meso-tetra(pentafluorophenyl)porphyrin using 1-mercapto-orthocarborane [30] and 1-mercaptomethyl-1,12-carborane [12,31].
The structures of the new BODIPYs 3, 5, and 6 were confirmed by 1H- and 13CNMR, mass spectrometry, UV-Vis and fluorescence spectroscopies. We have previously
reported the X-ray structure and spectroscopic properties of BODIPY 7 [19]. A single
crystal of 6 suitable for X-ray analysis (see Figure 1) was grown from slow evaporation
of hexane. The X-ray crystal structure revealed the expected approximate planarity of the
C3BN2 ring of the BODIPY core, with mean deviation of 0.040 Å (average of two
independent molecules). The other six pyrrole carbon atoms tip out of this plane by up to
0.246 Å, and the S atom of the 8-thiocarborane group lies out of plane on the opposite
side by 0.335 Å (average of two). The boron atom possesses tetrahedral geometry with
the BF2 groups lying nearly perpendicular to the BODIPY core, forming a dihedral angle
of 89.1° (average of two) with the C3BN2 ring. In the 1H-NMR spectra in CDCl3,
significant difference was observed in the chemical shifts of the 1,7-methyl groups of 6
compared with those of 3 and 5. The presence of the electron-withdrawing sulfur at the 8position caused a downfield shift in the chemical shift to 2.5 ppm, compared to the
shielding effect of the phenyl ring in 3 and 5, causing the 1,7-methyl groups to appear
between 1.3-1.4 ppm. On the other hand, the BH protons were observed as a broad signal
between 1-3 ppm for all carboranylBODIPYs. BODIPYs 3, 5, 6 and 7 allowed us to
investigate the effects of the position (8 versus 2,6) and the nature of the carborane cages
(ortho versus para), on the spectroscopic properties and BBB permeability of this type of
compounds (vide infra).
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Figure 1. Molecular structure of 6 from X-ray crystal structure determination. Ellipsoids
are drawn at the 50% probability level. Selected distances are S1-C5 1.7797(8), S1-C14
1.7949(8), B1-F1 1.3994(10), B1-F2 1.3875(10), B1-N1 1.5438(11), B1-N2 1.5405(11),
C14-C15 1.6618(11) Å.

3.2. Spectroscopic properties
The spectroscopic properties of BODIPYs 3, and 5-7 were evaluated in DMSO,
and the results are summarized in Table 1. The fluorescence quantum yields were
calculated using rhodamine 6G in ethanol (ΦF = 0.95) as the standard. The carboranylBODIPYs displayed spectra characteristic of boron dipyrromethene dyes with strong
absorption bands (log ε = 4.4 - 4.8) corresponding to the S0-S1 (π-π*) transitions,
accompanied by a shoulder at slightly lower wavelength attributed to vibrational
transitions. The absorption max for BODIPYs 3, 6 and 7 were red-shifted by about 30 nm
compared to BODIPY 5 due to 8-sulfur substitution [19] or 2,6-aryl substitution [25],
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respectively. The Stokes’ shifts varied between 7 – 27 nm, the larger value observed for
BODIPY 3, as a result of 2,6-aryl substitution, as previously observed [25]. BODIPYs 6
and 7 were poorly emissive in DMSO, as previously reported for 8-sulfur substituted
BODIPYs [19,32], while in contrast BODIPYs 3 and 5 showed high fluorescence
quantum yields, demonstrating that the ortho-carborane clusters do not quench the
fluorescence of boron dipyrromethene dyes. This result is in agreement with previous
reports showing that closo-carboranes generally enhance the fluorescence of
chromophores [33,34].

Table 1. Photophysical properties of BODIPYs 3 and 5-7 in DMSO.
λmax abs

λmax em

(nm)

(nm)

3

534

561

4.38

0.99

27

5

501

508

4.81

0.99

7

6

538

n/a

4.37

<0.01

n/a

7

531

545

4.68

0.03

14

Compound

log ε

ΦF

Stokes
Shift (nm)

3.3. In vitro BBB Permeability
The BBB permeability of BODIPYs 3 and 5-7 was investigated using the human
brain endothelial cell line hCMEC/D3 as BBB model [7-9]. The permeabilities were
evaluated by determining the permeability coefficients (Pe), as previously described [12]
and the results are shown in Table 2. Only one carboranyl-BODIPY, 6, showed higher
permeability than the standard lucifer yellow (determined Pe = 25.23 ± 0.88 x 10-6 cm/s),
probably as a result of its lower molecular weight and lower hydrophobic character, as
measured by the partition coefficients in 1-octanol-HEPES, in comparison with the other
BODIPYs. BODIPYs 3 and 5 in which the carborane moiety is conjugated to the
BODIPY core via a phenyl spacer, were more hydrophobic and showed decreased
solubility in the cellular medium compared with 6 and 7; this property, in addition to their
higher molecular weight compared with 6 and 7, resulted in lower permeabilities. The
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permeability of molecules across the hCMEC/D3 monolayer is known to depend on
molecular weight and hydrophobic character, and we have recently shown that a series of
carboranylporphyrins of larger molecular weights and hydrophobic characters compared
with the BODIPYs, also show relatively small Pe values in the order of 0.8-3.3 x 10-6
cm/s [12]. It is however remarkable that BODIPY 6 shows about 10-fold higher
permeability than the other BODIPYs tested, and we are currently investigating other
cellular properties of carboranyl-BODIPYs, including cytotoxicity and uptake.

Table 2. Permeabilty coefficients (Pe) using human endothelium hCMEC/D3 cells, and
partition coefficients (log P) in 1-octanol-HEPES buffer for BODIPYs.
BODIPY

Pe x 10-6 (cm/s)

log P

3

0.05±0.02

1.41

5

0.10±0.003

1.35

6

38.75±1.12

0.85

7

0.38±0.006

0.89

4. Conclusions
The synthesis, spectroscopic properties and BBB permeability, using the human brain
endothelial cell line hCMEC/D3 as BBB model, of four BODIPYs were investigated.
Two different synthetic routes, Pd(0)-catalyzed Suzuki cross-coupling and nucleophilic
substitution reactions on halogenated BODIPYs, were employed for attachment of the
carborane moieties to the BODIPY scaffold. Studies of the spectroscopic properties of
this series of BODIPYs revealed strong absorptions at 501-538 nm and emissions at 508561 nm, with high fluorescence quantum yields (f = 0.99) for the 8-aryl-BODIPYs and
very low (f < 0.04) for the 8-sulfo-BODIPYs. The BBB permeability assessment of the
four carboranyl-BODIPYs revealed that only BODIPY 6 shows higher permeability (Pe
=3.9 x 10-5 cm/s) than lucifer yellow, probably as a result of its lower molecular weight
and lower hydrophobic character (log P = 0.85) compared with the other BODIPYs.
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